Prescribing High-Priced Cancer Drugs: Rethinking Physicians' Choice Regarding Expensive Treatments

As the prices of cancer treatments are constantly rising, reaching tens and hundreds of thousands of euros per patient, this article examines the existence and impact of these prices in everyday hospital practice and in relation to medical autonomy. Our study takes place in the French health care system, which is characterized by the coverage of health care costs by the health insurance system. Through ethnographic observations carried out in hematology and thoracic oncology departments, the study explores how prices, although invisible and excluded from medical practice, can come into play in situations of tension at the boundaries of medical, administrative and financial prescriptive frameworks. However, this paper shows how the innovative and complex nature of these costly treatments can be reinterpreted in terms of value and even become a source of credit.